AMOIA, PASQUALE
 Distribuzione geografica
Continente #
EU - Europa 38
NA - Nord America 9
AS - Asia 7
Totale 54
Nazione #
IT - Italia 21
US - Stati Uniti d'America 9
FR - Francia 4
IN - India 4
SE - Svezia 4
CZ - Repubblica Ceca 3
ES - Italia 3
VN - Vietnam 2
GR - Grecia 1
IE - Irlanda 1
IL - Israele 1
RU - Federazione Russa 1
Totale 54
Città #
Chieti 17
Stockholm 4
Boardman 3
Dong Ket 2
Hubli 2
Vallirana 2
Alpharetta 1
Ashburn 1
Athens 1
Bhopal 1
Columbus 1
Como 1
Dublin 1
Kumar 1
Laurel 1
Montesilvano Marina 1
Mountain View 1
Redmond 1
Yehud 1
Totale 43
Nome #
Antiglioma Activity of Aryl and Amido-Aryl Acetamidine Derivatives Targeting iNOS: Synthesis and Biological Evaluation, file e4233f17-b301-2860-e053-6605fe0a460a 32
Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-L-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma, file e4233f19-5add-2860-e053-6605fe0a460a 10
Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-L-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma, file e4233f16-d09a-2860-e053-6605fe0a460a 8
New amidine-benzenesulfonamides as iNOS inhibitors for the therapy of the triple negative breast cancer, file ad725347-bdd1-40ea-8c04-238d25cb3b67 2
Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome, file e4233f17-7884-2860-e053-6605fe0a460a 2
The Selective Acetamidine-Based iNOS Inhibitor CM544 Reduces Glioma Cell Proliferation by Enhancing PARP-1 Cleavage In Vitro, file e4233f17-1c68-2860-e053-6605fe0a460a 1
Totale 55
Categoria #
all - tutte 297
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 297


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 0 1 0
2019/20203 0 0 0 0 0 0 0 0 1 0 2 0
2020/202110 0 1 0 0 0 4 0 0 1 0 1 3
2021/202214 0 1 2 1 1 0 1 0 3 0 3 2
2022/202318 1 2 0 0 0 4 2 1 1 1 4 2
2023/20249 1 1 0 0 0 2 2 0 2 0 1 0
Totale 55